DCS and MBC Joint Seminar: TONI CELIÀ-TERRASSA "LCOR implications in breast cancer immunity and therapeutic opportunities"

About

Division of Cancer Sciences (DCS) and Manchester Breast Centre (MBC) Joint Seminar Dr Toni Celia-Terrassa Cancer Cell States & Metastasis Immunity Lab at the Hospital del Mar Research Institute, Barcelona, Spain Title: LCOR implications in breast cancer immunity and therapeutic opportunities. Host: Bruno Simões Date: Monday 19th October 2026 Time: 2pm Venue: Oglesby Cancer Research Building, 555 Wilmslow Rd, Manchester M20 4GJ TONI CELIÀ-TERRASSA, PHD. Group Leader of the Cancer Cell States & Metastasis Immunity Lab at the Hospital del Mar Research Institute (HMRI). His scientific career is driven by a central objective: to understand how cancer cell-state plasticity and immune surveillance shape breast cancer metastasis, and how these principles can be therapeutically exploited. He obtained his PhD in 2012 at the IBMB-CSIC / University of Barcelona under the supervision of Dr. Timothy Thomson, where his doctoral work provided paradigm-shifting insights into epithelial-to-mesenchymal transition (EMT) plasticity, revealing how embryonic stem cell–like programs and their reversion govern metastatic competence and colonization. He then pursued postdoctoral training (2012–2017) at Princeton University in the laboratory of Dr. Yibin Kang, a world leader in breast cancer metastasis research. During more than five years at Princeton, he specialized in mammary stem cell programs driving metastasis and uncovered mechanisms by which normal and malignant stem cells evade immune surveillance, elucidating the spatiotemporal dynamics of EMT–MET transitions within the metastatic microenvironment. Since establishing his independent group in 2018, the lab integrates cancer cell-state dynamics, stem cell biology, and tumor immunology to develop innovative immunotherapeutic and immunopreventive strategies. The group has contributed key conceptual advances, including the identification of immune-evasive cancer stem cell states, the distinctive immunology of micrometastasis, and the demonstration that mRNA-based therapies can be used to therapeutically modulate cancer cell states. https://celiaterrassalab.com/ [celiaterrassalab.com] Recent publications: JCI - Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak: Cancer Cell LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer | Nature Cancer